It is well established that obesity is associated with higher risk of hepatocellular carcinoma (HCC) in the general population.
1 However, it is unclear whether body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]) is associated with the risk of HCC in patients with chronic hepatitis B virus (HBV) infection because previous studies have reported inconsistent results. 2, 3 In this study, using data from a large nationwide, population-based cohort database, we provide clinical evidence on the association between BMI and development of HCC among men and women with chronic HBV infection.
Methods | We used the National Health Insurance Service (NHIS) data, which provides compulsory health insurance coverage and national health screening for all citizens in the Republic of Korea. The institutional review board (IRB) at the Seoul National University Hospital approved our study. We identified adult men and women (age ≥18 years) with chronic HBV infection who underwent health examinations between January 1, 2002, and December 31, 2006 , in the NHIS database. We excluded patients with a history of cancer and those who died before the follow-up period. The patients were grouped into the BMI categories based on the World Health Organization classification for Asian populations. Patients were followed up from January 1, 2007 , to December 31, 2015 , and censored at the event of HCC, death, or end of follow-up, whichever occurred first. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% CIs across the BMI categories using 18.5 to 22.9 as the reference group, and we graphically assessed the strength of the relationship between BMI and HCC with restricted cubic spline models in men and women for BMI categories and covariates (Table) . Partial likelihood ratio tests in the Cox regression model were used to compare the magnitude of the association of BMI with HCC between men and women. Sensitivity analyses were conducted by excluding events of HCC up to 4 years, as well as patients with liver comorbidities. Results | Our study cohort of patients with chronic HBV infection comprised of 214 167 men and 156 155 women. During the 8 years of follow-up, there were 11 241 HCCs in men and 3368 HCCs in women. The risk of HCC was positively associated with BMI in a dose-response manner both in men (P trend < .01) and women (P trend < .001). In severely obese men and women (BMI≥30), the HR for HCC were 1.22 (95% CI, 1.09-1.36) and 1.46 (95% CI, 1.24-1.71) compared with those whose BMI was between 18.5 and 22.9 (Table) . The magnitude of the association between BMI and HCC was stronger in women who were overweight compared with men (P < .001). The correlation between BMI and HCC was also higher in women compared with men ( Figure) . Similar results were found in the sensitivity analyses.
Discussion | Our study showed that BMI is significantly associated with higher risk of HCC among patients with chronic HBV infection, and that the risk may differ by sex. The relationship between BMI and risk of HCC was significant and independent of underlying liver diseases in patients with chronic HBV infection. The difference between male and female patients with chronic HBV infection found in our study may be partially explained by the sex difference in the relationship of BMI to total body fat. 4 A major limitation of our study should be noted: the NHIS database lacked information on serum HBV DNA levels, which is a clinically important predictor for the development of liver cirrhosis and HCC among patients with chronic HBV infection. 5 Our findings have both clinical and public health implications that support the need for intervention strategies and medical attention for obese patients with chronic HBV infection, especially in women. The models were fitted with restricted cubic splines with 4 knots placed at the 5th, 35th, 65th, and 95th percentiles of BMI (model selection and knot placement via Bayesian information criterion). The solid line represents the hazard ratio, and the broken lines represent corresponding 95% CI. The reference BMI is the 18.5 to 22.9 category, and the curves were adjusted for variables in a multivariable model including sociodemographic factors (age, residential area, and insurance premium), lifestyle factors (smoking status, alcohol use, physical activity), health status (fasting serum glucose level, total cholesterol level, alanine aminotransferase level), medication use (aspirin, metformin, nonsteroidal anti-inflammatory drug, statin, anti-HBV treatment), and comorbidities (liver cirrhosis, alcoholic liver disease, nonalcoholic fatty liver disease, hepatitis C virus coinfection, Charlson comorbidity index). BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); HBV, hepatitis B virus.
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Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFRMutant Advanced Non-Small Cell Lung Cancer
Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrates superior efficacy, compared with chemotherapy, for patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, approximately 20% to 30% of patients who receive such treatment exhibit de novo resistance to therapy with EGFR TKIs.
2 A better understanding of the underlying mechanisms of this phenomenon is imperative to optimize clinical outcomes.
Methods | This retrospective cohort study (conducted from January 1, 2012, to April 30, 2014) included 58 patients with metastatic NSCLC associated with EGFR (OMIM 131550) mutation (determined in tumor tissue) treated with first-line EGFR TKIs. The institutional review board of Sun Yat-sen University Cancer Center approved the study, and all of the patients provided written informed consent. Cell-free DNA obtained before treatment was subjected to next-generation sequencing of 49 cancer-related genes with use of a kit (Ion Pi Sequencing 200 kit v2; Thermo Fisher Scientific), as reported elsewhere, at a mean depth of 15 370X. 3 The association between response and concomitant mutation was determined by logistic regression analysis. Data were analyzed from April 30 through November 30, 2017. Kaplan-Meier survival curves and Cox proportional hazards regression analysis were performed, and hazard ratios (HRs) and 95% CIs were calculated to determine the survival difference. Statistical significance was defined as a 2-sided P < .05.
Results | Among the 58 patients, the median age was 58.5 years (range, 40-81 years), 28 (48%) were male, 11 (19%) were smokers, and 56 (97%) had adenocarcinoma. Median progression-free survival and overall survival were 11.53 months (95% CI, 7.90-15.17) and 41.23 months (95% CI, not computable), respectively. Median survival time and 95% CIs are provided appropriately in the Figure, B Fisher test, P = .02) were significantly associated with a higher incidence of concomitant mutation (Figure, A) .
Concomitant mutation was significantly associated with reduced objective response rate (44% vs 77%; P = .01), shorter duration of progression-free survival (Figure, B; median survival, 6.20 months (95% CI, (Table) .
Discussion | Similar to a recent study, our results might challenge the current view that EGFR-mutant NSCLC is a singleoncogene-driven disease. 4 This study also reveals the widespread existence of concomitant mutations in patients with EGFR-mutant advanced NSCLC. In addition, genetic coalterations negatively affect the response and survival of patients who receive first-line treatment with EGFR TKIs, plausibly because of the bypass activation of survival signaling pathways or tumor heterogeneity. Patients with EGFR exon 19 deletion were found to have longer survival than those with exon 21 mutation, although the underlying mechanisms remain unknown.
5 Of interest, we found that patients with exon 21 mutation had a significantly higher incidence of concomitant mutation. In multivariable analysis, the EGFR subtype was no longer significantly associated with survival, which suggests that the inferior treatment outcome associated with exon 21 mutation could be attributed to or confounded by the higher incidence of concomitant mutation. The presence of EGFR T790M mutation at baseline also was associated with poorer efficacy of first-generation EGFR TKIs, which provides a rationale for the superiority of osimeritinib therapy over therapy with earlier-generation TKIs in untreated EGFRmutant NSCLC.
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Major limitations of this study were the sample size, the single-centered design, and the lack of serial biopsies. In addition, the data from our hot spot next-generation sequencing (not including other mutations, copy number alterations, or chromosomal abnormalities) might represent an underestimation of concomitant mutation and prevent an in-depth analysis of signaling pathway or clonality.
These limitations aside, our results suggest that the common presence of co-occurring genetic alterations may be associated with resistance to EGFR TKIs in patients with
